Meeting Report: ESC Forum on Drug Eluting Stents European Heart House, Nice, 27-28 September 2007

Fajadet, Jean; Kristensen, Steen Dalby; Aimonetti, A.; Allocco, Dominic J.; Baczyńska, Anna; Bagust, A; Berenger, M.; Bos, Gert; Boam, Ashley B.; Bowen, James M.; Braunwald, Eugene; Calle, J. Puig La; Camenzind, Edoardo; Campo, Gianluca; Carlier, Stéphane; Chevalier, Bernard; Daemen, Joost; Schepper, Jean De; Bisceglie, G. Di; DiMario, Carlo; Dobbels, H.; Fajadet, Jean; Farb, Andrew; Ghislain, J.C.; Gitt, Anselm K.; Guagliumi, Giulio; Hellbardt, S.; Hillege, Hans L.; Hoedt, R. ten; Isaia, C.; James, Stefan; Jong, Peter de; Jüni, Peter; Kastrati, Adnan; Klasen, Elizabeth M.; Kloth, Sabine; Krucoff, Mitchell W.; Legrand, Victor; Lekehal, Malik; LeNarz, LeRoy; Mhullain, Fiona Ni; Nagai, Hirofumi; Patteet, A.; Paunovic, Dragica; Pfisterer, Matthias; Potgieter, A.; Purdy, Isabell B.; Raveau-Landon, C; Rothman, Martin T.; Serruys, Patrick W.; Silber, Sigmund; Simoons, Maarten L.; Steg, Philippe Gabríel; Tariah, Ibrahim; Ternstrom, S.; Wuytswinkel, J. Van; Waliszewski, Matthias; Wallentin, Lars; Wijns, William; Windecker, Stephan

doi:10.1093/eurheartj/ehn510

Cited by 23 publications

(10 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, due to a 20 30% rate of recurrence of angiographic stenosis within 6 9 months after implantation, restenosis within BMS has often been called the Achilles' heel of PCI. In native vessels, DES significantly reduce angiographic restenosis and ischaemiadriven TVR [45,215]. In RCTs, no significant differences were observed in the long-term rates of death or MI after DES or BMS use for either off-label or on-label indications [45,46].…”

Section: Drug-eluting Stentsmentioning

confidence: 99%

“…In non-randomized large registry studies, DES use may reduce death and MI [46]. First-generation DES are safe and efficacious for both on-label and off-label use, when implanted in the native circulation, in spite of a slightly increased propensity for late and very late stent thrombosis [215]. Long-term results ( 5 years) are only available for SES, PES, and zotarolimus-eluting stent (ZES).…”

Section: Drug-eluting Stentsmentioning

confidence: 99%

See 1 more Smart Citation

Guidelines on myocardial revascularization

Wijns¹,

Kolh²,

Danchin³

et al. 2011

Revista Portuguesa de Cardiologia (English Edition)

238

317

View full text Add to dashboard Cite

Section: Drug-eluting Stentsmentioning

confidence: 99%

Section: Drug-eluting Stentsmentioning

confidence: 99%

Guidelines on myocardial revascularization

Wijns¹,

Kolh²,

Danchin³

et al. 2011

Revista Portuguesa de Cardiologia (English Edition)

238

317

View full text Add to dashboard Cite

Section: Drug-eluting Stentsmentioning

confidence: 99%

Section: Drug-eluting Stentsmentioning

confidence: 99%

Guidelines on myocardial revascularization

Kolh

Wijns

Danchin³

et al. 2010

European Journal of Cardio-Thoracic Surgery

400

101

View full text Add to dashboard Cite

Guidelines and Expert Consensus Documents summarize and\ud evaluate all available evidence with the aim of assisting\ud physicians in selecting the best management strategy for an\ud individual patient suffering from a given condition, taking\ud into account the impact on outcome and the risk benefit\ud ratio of diagnostic or therapeutic means. Guidelines are no\ud substitutes for textbooks and their legal implications have\ud been discussed previously. Guidelines and recommendations should help physicians to make decisions in their daily\ud practice. However, the ultimate judgement regarding the\ud care of an individual patient must be made by his/her\ud responsible physician(s).\ud The recommendations for formulating and issuing ESC\ud Guidelines and Expert Consensus Documents can be found\ud on the ESC website (http://www.escardio.org/knowledge/\ud guidelines/rules).\ud Members of this Task Force were selected by the European\ud Society of Cardiology (ESC) and the European Association for\ud Cardio-Thoracic Surgery (EACTS) to represent all physicians\ud involved with the medical and surgical care of patients\ud with coronary artery disease (CAD). A critical evaluation\ud of diagnostic and therapeutic procedures is performed\ud including assessment of the risk benefit ratio. Estimates\ud of expected health outcomes for society are included,\ud where data exist. The level of evidence and the strength\ud of recommendation of particular treatment options are\ud weighed and graded according to predefined scales, as\ud outlined in Tables 1 and 2.\ud The members of the Task Force have provided disclosure\ud statements of all relationships that might be perceived as\ud real or potential sources of conflicts of interest. These\ud disclosure forms are kept on file at European Heart House,\ud headquarters of the ESC. Any changes in conflict of interest\ud that arose during the writing period were notified to the ESC.\ud The Task Force report received its entire financial support\ud from the ESC and EACTS, without any involvement of the\ud pharmaceutical, device, or surgical industry.\ud ESC and EACTS Committees for Practice Guidelines are\ud responsible for the endorsement process of these joint\ud Guidelines. The finalized document has been approved by all\ud the experts involved in the Task Force, and was submitted to\ud outside specialists selected by both societies for review. The\ud document is revised, and finally approved by ESC and EACTS and subsequently published simultaneously in the European\ud Heart Journal and the European Journal of Cardio-Thoracic\ud Surgery.\ud After publication, dissemination of the Guidelines is of\ud paramount importance. Pocket-sized versions and personal\ud digital assistant-downloadable versions are useful at the\ud point of care.\ud Some surveys have shown that the intended users are\ud sometimes unaware of the existence of guidelines, or simply\ud do not translate them into practice. Thus, implementation\ud programmes are needed because it has been shown that\ud the outcome of dis...

show abstract

“…Clinical outcomes were similar across stent types, even though most confidence intervals were wide and compatible with both, substantial advantages and disadvantages of TiNOX stents over SES or PES. The duration of dual antiplatelet therapy in patients who underwent implantation of a drug-eluting stent is established at six months or more 18,19 . In view of the reduced duration of dual antiplatelet therapy possibly required for the TiNOX stent, we suggest that TiNOX stents may be an alternative to drug-eluting stents, particularly in patients with relative or absolute contraindications to prolonged dual antiplatelet therapy.…”

Section: Tinox Stents Versus Ses and Pesmentioning

confidence: 99%

Clinical long-term outcome after implantation of titanium nitride-oxide coated stents compared with paclitaxel- or sirolimus-eluting stents: propensity-score matched analysis

Limacher¹,

Räber²,

Laube³

et al. 2012

EuroIntervention

View full text Add to dashboard Cite

Aims: We performed a propensity score matched analysis to explore whether TiNOX stents are superior to paclitaxel-(PES) and sirolimus-eluting stents (SES) in routine clinical practice. Methods and results:A total of 1,607 patients undergoing implantation of SES, PES or TiNOX stents were prospectively entered into a stent registry and followed up for three years. Using propensity score matching, we compared clinical outcome among 319 pairs of patients treated with TiNOX stents or SES and 337 pairs of patients treated with TiNOX stents or PES. The primary outcome MACE, a composite of death, myocardial infarction, and target vessel revascularisation occurred in 20% of patients with TiNOX stents, 19% of patients with SES and 23% of patients with PES at 3-years. The hazard ratio was 1.00 comparing TiNOX stents with SES (95% CI 0.69-1.45, p=1.00), and 0.95 comparing TiNOX stents with PES (95% CI 0.66-1.36, p=0.78). Conclusions:We did not find evidence to suggest superiority of TiNOX stents over SES or PES. In view of similar clinical outcomes, but with the reduced duration of dual antiplatelet therapy used with the TiNOX stent, we suggest that TiNOX stents may be an alternative to drug-eluting stents in patients unsuitable for long-term dual antiplatelet therapy. KEYWORDS

show abstract

Meeting Report: ESC Forum on Drug Eluting Stents European Heart House, Nice, 27-28 September 2007

Cited by 23 publications

References 36 publications

Guidelines on myocardial revascularization

Guidelines on myocardial revascularization

Guidelines on myocardial revascularization

Clinical long-term outcome after implantation of titanium nitride-oxide coated stents compared with paclitaxel- or sirolimus-eluting stents: propensity-score matched analysis

Contact Info

Product

Resources

About